688580 伟思医疗
交易中 12-24 13:39:43
资讯
新帖
简况
伟思医疗跌5% 8券商建议增持
智选洞察 · 12-23 09:56
伟思医疗跌5% 8券商建议增持
伟思医疗(688580)12月19日主力资金净卖出5.88万元
证券之星 · 12-20
伟思医疗(688580)12月19日主力资金净卖出5.88万元
伟思医疗涨6.72%,中泰证券一个月前给出“买入”评级
证券之星 · 12-18
伟思医疗涨6.72%,中泰证券一个月前给出“买入”评级
伟思医疗涨5% 个人养老金制度推广
智选洞察 · 12-18
伟思医疗涨5% 个人养老金制度推广
伟思医疗(688580)12月17日主力资金净卖出643.69万元
证券之星 · 12-18
伟思医疗(688580)12月17日主力资金净卖出643.69万元
12月17日伟思医疗跌8.12%,前海联合泳涛混合A基金重仓该股
证券之星 · 12-17
12月17日伟思医疗跌8.12%,前海联合泳涛混合A基金重仓该股
伟思医疗跌5% 8券商建议增持
智选洞察 · 12-17
伟思医疗跌5% 8券商建议增持
伟思医疗创近1月新高 8家券商建议买入
智选洞察 · 12-16
伟思医疗创近1月新高 8家券商建议买入
伟思医疗12月13日获主力加仓506万元 环比增加1104.76%
市场透视 · 12-13
伟思医疗12月13日获主力加仓506万元 环比增加1104.76%
伟思医疗创近1月新高 8家券商建议买入
智选洞察 · 12-13
伟思医疗创近1月新高 8家券商建议买入
伟思医疗新注册《伟思康复骑士游戏软件V1.0》项目的软件著作权
证券之星 · 12-13
伟思医疗新注册《伟思康复骑士游戏软件V1.0》项目的软件著作权
【机构调研记录】泓德基金调研华测检测、伟思医疗等4只个股(附名单)
证券之星 · 12-02
【机构调研记录】泓德基金调研华测检测、伟思医疗等4只个股(附名单)
伟思医疗:11月26日投资者关系活动记录,中信建投、德邦基金等多家机构参与
证券之星 · 11-29
伟思医疗:11月26日投资者关系活动记录,中信建投、德邦基金等多家机构参与
11月22日伟思医疗跌5.82%,前海联合泳涛混合A基金重仓该股
证券之星 · 11-22
11月22日伟思医疗跌5.82%,前海联合泳涛混合A基金重仓该股
伟思医疗跌5% 7家券商增持
智选洞察 · 11-22
伟思医疗跌5% 7家券商增持
伟思医疗获2项医疗器械注册证 涉及多功能生物刺激反馈仪
财中社 · 11-18
伟思医疗获2项医疗器械注册证 涉及多功能生物刺激反馈仪
伟思医疗(688580.SH)取得2项医疗器械注册证
智通财经 · 11-18
伟思医疗(688580.SH)取得2项医疗器械注册证
伟思医疗(688580)11月14日主力资金净卖出952.77万元
证券之星 · 11-15
伟思医疗(688580)11月14日主力资金净卖出952.77万元
伟思医疗11月14日遭主力抛售831万元 环比增加160.50%
市场透视 · 11-14
伟思医疗11月14日遭主力抛售831万元 环比增加160.50%
伟思医疗大跌5.14% 7家券商给予增持建议
智选洞察 · 11-14
伟思医疗大跌5.14% 7家券商给予增持建议
加载更多
公司概况
公司名称:
南京伟思医疗科技股份有限公司
所属行业:
专用设备制造业
上市日期:
2020-07-21
主营业务:
南京伟思医疗科技股份有限公司主营业务为医疗器械的研发、生产和销售,公司产品主要是MyOnyx生物刺激反馈仪、瑞翼生物刺激反馈仪、经颅磁刺激仪、盆底磁刺激仪、脉冲磁场治疗仪、脉冲磁恢复仪、脉冲磁塑形仪、多参数生物反馈仪、团体生物反馈仪、表面肌电分析系统、新生儿脑电测量仪、X-walk、X-locom、科瑞达钬激光治疗机、阴道电极、直肠电极、盆底训练探头、盆底肌肉康复器、认知功能障碍治疗软件、伟思云。
发行价格:
67.58
{"stockData":{"symbol":"688580","market":"SH","secType":"STK","nameCN":"伟思医疗","latestPrice":29.92,"timestamp":1735018783000,"preClose":29.84,"halted":0,"volume":518959,"delay":0,"floatShares":95771299,"shares":95771299,"eps":1.1773,"marketStatus":"交易中","marketStatusCode":2,"change":0.08,"latestTime":"12-24 13:39:43","open":29.82,"high":30.4,"low":29.67,"amount":15575600,"amplitude":0.0245,"askPrice":29.96,"askSize":98,"bidPrice":29.92,"bidSize":2,"shortable":0,"etf":0,"ttmEps":1.1773,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1735023600000},"adr":0,"adjPreClose":29.84,"symbolType":"stock_kcb","openAndCloseTimeList":[[1735003800000,1735011000000],[1735016400000,1735023600000]],"highLimit":32.82,"lowLimit":26.86,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":95771288,"pbRate":1.77,"roa":"--","roe":"4.8%","epsLYR":1.9969,"committee":-0.7343,"marketValue":2865000000,"floatMarketCap":2865000000,"peRate":25.414084,"changeRate":0.0027,"turnoverRate":0.0054,"status":0},"requestUrl":"/m/hq/s/688580","defaultTab":"news","newsList":[{"id":"2493702942","title":"伟思医疗跌5% 8券商建议增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2493702942","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493702942?lang=zh_cn&edition=full","pubTime":"2024-12-23 09:56","pubTimestamp":1734919011,"startTime":"0","endTime":"0","summary":"12月23日,伟思医疗股价大幅下跌,截至09点56分,伟思医疗下跌5.22%,报30.35元/股,成交1818万元,换手率0.61%,振幅6.03%。此外,数据统计显示,近半年内8家券商给予增持建议,8家券商给予买入建议。资金动向截止发稿,伟思医疗获得主力净流出515万元,其中超大单流出390万元,大单流出124万元。最新财报显示,今年三季报,伟思医疗实现营业收入2.92亿元,同比减少12.06%,净利润为7,816.63万元,同比减少23.13%,基本每股收益为0.82元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223095710ab8c9ca7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223095710ab8c9ca7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688580"],"gpt_icon":0},{"id":"2492431253","title":"伟思医疗(688580)12月19日主力资金净卖出5.88万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492431253","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492431253?lang=zh_cn&edition=full","pubTime":"2024-12-20 08:22","pubTimestamp":1734654156,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年12月19日收盘,伟思医疗报收于31.75元,下跌4.34%,换手率1.81%,成交量1.74万手,成交额5547.92万元。伟思医疗主营业务:主要从事医疗器械的研发、生产和销售,以研发创新为发展驱动力,持续投入在电刺激、磁刺激、电生理、康复机器人以及医美能量源等方向的先进技术研发,并完善产品布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122000006536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","BK0251"],"gpt_icon":0},{"id":"2492971303","title":"伟思医疗涨6.72%,中泰证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2492971303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492971303?lang=zh_cn&edition=full","pubTime":"2024-12-18 16:12","pubTimestamp":1734509549,"startTime":"0","endTime":"0","summary":"今日伟思医疗(688580)涨6.72%,收盘报33.19元。2024年10月25日,中泰证券研究员祝嘉琦,谢木青,于佳喜发布了对伟思医疗的研报《盆底、康复逐步企稳,看好医美等新品放量》,该研报对伟思医疗给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为79.85%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为中泰证券的于佳喜。伟思医疗(688580)个股概况:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121800027126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","600918"],"gpt_icon":0},{"id":"2492839903","title":"伟思医疗涨5% 个人养老金制度推广","url":"https://stock-news.laohu8.com/highlight/detail?id=2492839903","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492839903?lang=zh_cn&edition=full","pubTime":"2024-12-18 11:25","pubTimestamp":1734492329,"startTime":"0","endTime":"0","summary":"消息解读近期,个人养老金制度的全国推广及产品扩容引发了广泛关注。12月15日,个人养老金制度正式从试点36个城市推向全国,这一举措标志着养老保障体系从区域性试验迈向全面普惠的新阶段。同时,证监会公布了最新的个人养老金产品目录,其中首批85只权益类指数基金被纳入,进一步扩大了个人养老金账户的投资范围。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218112629984c9fe5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218112629984c9fe5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688580","BK0251"],"gpt_icon":0},{"id":"2492948974","title":"伟思医疗(688580)12月17日主力资金净卖出643.69万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492948974","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492948974?lang=zh_cn&edition=full","pubTime":"2024-12-18 08:25","pubTimestamp":1734481533,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年12月17日收盘,伟思医疗报收于31.1元,下跌8.12%,换手率2.17%,成交量2.08万手,成交额6642.39万元。伟思医疗主营业务:主要从事医疗器械的研发、生产和销售,以研发创新为发展驱动力,持续投入在电刺激、磁刺激、电生理、康复机器人以及医美能量源等方向的先进技术研发,并完善产品布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121800008631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688580"],"gpt_icon":0},{"id":"2492980378","title":"12月17日伟思医疗跌8.12%,前海联合泳涛混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492980378","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492980378?lang=zh_cn&edition=full","pubTime":"2024-12-17 16:16","pubTimestamp":1734423402,"startTime":"0","endTime":"0","summary":"证券之星消息,12月17日伟思医疗跌8.12%,收盘报31.1元,换手率2.17%,成交量2.08万手,成交额6642.39万元。根据2024基金Q3季报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为前海联合泳涛混合A。前海联合泳涛混合A目前规模为0.14亿元,最新净值1.265,较上一交易日下跌0.71%,近一年下跌12.68%。前海联合泳涛混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121700026787.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","BK0251"],"gpt_icon":0},{"id":"2492091856","title":"伟思医疗跌5% 8券商建议增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2492091856","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492091856?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:48","pubTimestamp":1734400123,"startTime":"0","endTime":"0","summary":"12月17日,伟思医疗股价大幅下跌,截至09点48分,伟思医疗下跌5.17%,报32.10元/股,成交1603万元,换手率0.51%,振幅5.70%。此外,数据统计显示,近半年内8家券商给予增持建议,8家券商给予买入建议。资金动向截止发稿,伟思医疗获得主力净流出8万元,其中超大单流出39万元,大单流入32万元。最新财报显示,今年三季报,伟思医疗实现营业收入2.92亿元,同比减少12.06%,净利润为7,816.63万元,同比减少23.13%,基本每股收益为0.82元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121709485395ea1e9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121709485395ea1e9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688580"],"gpt_icon":0},{"id":"2492610188","title":"伟思医疗创近1月新高 8家券商建议买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2492610188","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492610188?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:33","pubTimestamp":1734312839,"startTime":"0","endTime":"0","summary":"12月16日,伟思医疗股价大幅上涨,截至09点33分,伟思医疗上涨5.05%,报34.35元/股,创近1个月新高,成交698万元,换手率0.22%,振幅5.41%。此外,数据统计显示,近半年内8家券商给予增持建议,8家券商给予买入建议。资金动向截止发稿,伟思医疗获得主力净流入109万元,其中超大单流入68万元,大单流入40万元。最新财报显示,今年三季报,伟思医疗实现营业收入2.92亿元,同比减少12.06%,净利润为7,816.63万元,同比减少23.13%,基本每股收益为0.82元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121609345995e9f5d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121609345995e9f5d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688580"],"gpt_icon":0},{"id":"2491301666","title":"伟思医疗12月13日获主力加仓506万元 环比增加1104.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491301666","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491301666?lang=zh_cn&edition=full","pubTime":"2024-12-13 15:19","pubTimestamp":1734074353,"startTime":"0","endTime":"0","summary":"12月13日, 伟思医疗股价涨1.40%,报收32.70元,成交金额6558万元,换手率2.06%,振幅6.67%,量比1.93。伟思医疗今日主力资金净流入506万元,连续4日净流入,上一交易日主力净流入42万元,今日环比增加1104.76%。近一年数据显示,该股主力连续4日净流入后,次日上涨概率为50.00%,平均涨幅为2.64%。该股近5个交易日上涨8.57%,主力资金累计净流入1085万元;近20日主力资金累计净流出1553万元,其中净流出天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213153059ab74a346&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213153059ab74a346&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688580"],"gpt_icon":0},{"id":"2491016653","title":"伟思医疗创近1月新高 8家券商建议买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2491016653","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491016653?lang=zh_cn&edition=full","pubTime":"2024-12-13 10:15","pubTimestamp":1734056130,"startTime":"0","endTime":"0","summary":"12月13日,伟思医疗股价大幅上涨,截至10点15分,伟思医疗上涨5.05%,报33.88元/股,创近1个月新高,成交3395万元,换手率1.07%,振幅6.33%。此外,数据统计显示,近半年内8家券商给予增持建议,8家券商给予买入建议。资金动向截止发稿,伟思医疗获得主力净流入364万元,其中超大单流入289万元,大单流入75万元。最新财报显示,今年三季报,伟思医疗实现营业收入2.92亿元,同比减少12.06%,净利润为7,816.63万元,同比减少23.13%,基本每股收益为0.82元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213101535a1eaa2d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213101535a1eaa2d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688580","BK0251"],"gpt_icon":0},{"id":"2491133288","title":"伟思医疗新注册《伟思康复骑士游戏软件V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2491133288","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491133288?lang=zh_cn&edition=full","pubTime":"2024-12-13 01:15","pubTimestamp":1734023715,"startTime":"0","endTime":"0","summary":"证券之星消息,近日伟思医疗(688580)新注册了《伟思康复骑士游戏软件V1.0》项目的软件著作权。今年以来伟思医疗新注册软件著作权7个,较去年同期减少了22.22%。结合公司2024年中报财务数据,今年上半年公司在研发方面投入了2873.16万元,同比增11.8%。数据来源:企查查以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300000653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","BK0251"],"gpt_icon":0},{"id":"2488319613","title":"【机构调研记录】泓德基金调研华测检测、伟思医疗等4只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2488319613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488319613?lang=zh_cn&edition=full","pubTime":"2024-12-02 08:02","pubTimestamp":1733097770,"startTime":"0","endTime":"0","summary":"旗下最近一年表现最佳的公募基金产品为泓德数字经济混合发起式A,最新单位净值为1.11,近一年增长11.26%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200001045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0251","BK0159","BK0221","300012","LU1146622755.USD","688580","LU2460026573.USD","LU1820825898.SGD"],"gpt_icon":0},{"id":"2487755416","title":"伟思医疗:11月26日投资者关系活动记录,中信建投、德邦基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2487755416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487755416?lang=zh_cn&edition=full","pubTime":"2024-11-29 21:40","pubTimestamp":1732887645,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年11月29日伟思医疗发布公告称公司于2024年11月26日投资者关系活动记录,中信建投、德邦基金、浙商资管、西部证券、瑞和资本、人寿资产、招商医药、泓德基金、惠理集团、东方财富证券、申万菱信基金、永赢基金、鹤禧投资、Superstring 超弦资本、东方红资管、南土资产、万家基金、华富基金、天治基金参与。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112900041286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0276","688580","601066","BK0251"],"gpt_icon":0},{"id":"2485233695","title":"11月22日伟思医疗跌5.82%,前海联合泳涛混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485233695","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485233695?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:22","pubTimestamp":1732263758,"startTime":"0","endTime":"0","summary":"证券之星消息,11月22日伟思医疗跌5.82%,收盘报28.81元,换手率0.9%,成交量8651.0手,成交额2564.08万元。根据2024基金Q3季报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为前海联合泳涛混合A。前海联合泳涛混合A目前规模为0.14亿元,最新净值1.2549,较上一交易日下跌0.44%,近一年下跌17.33%。前海联合泳涛混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112200025898.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","BK0251"],"gpt_icon":0},{"id":"2485328961","title":"伟思医疗跌5% 7家券商增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2485328961","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485328961?lang=zh_cn&edition=full","pubTime":"2024-11-22 14:39","pubTimestamp":1732257575,"startTime":"0","endTime":"0","summary":"11月22日,伟思医疗股价大幅下跌,截至14点39分,伟思医疗下跌5.20%,报29.00元/股,失守30元整数关口,成交2236万元,换手率0.78%,振幅5.20%。此外,数据统计显示,近半年内7家券商给予增持建议,9家券商给予买入建议。资金动向截止发稿,伟思医疗获得主力净流出301万元,其中超大单流出77万元,大单流出223万元。最新财报显示,今年三季报,伟思医疗实现营业收入2.92亿元,同比减少12.06%,净利润为7,816.63万元,同比减少23.13%,基本每股收益为0.82元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122145555a24d33da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122145555a24d33da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688580","BK0251"],"gpt_icon":0},{"id":"2484697617","title":"伟思医疗获2项医疗器械注册证 涉及多功能生物刺激反馈仪","url":"https://stock-news.laohu8.com/highlight/detail?id=2484697617","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484697617?lang=zh_cn&edition=full","pubTime":"2024-11-18 16:02","pubTimestamp":1731916968,"startTime":"0","endTime":"0","summary":"财中社11月18日电伟思医疗 发布关于自愿披露取得医疗器械注册证的公告。公司近日收到了江苏省药品监督管理局颁发的2项《医疗器械注册证》,包括多功能生物刺激反馈仪和生物刺激反馈仪。多功能生物刺激反馈仪主要用于神经和肌肉功能的恢复,适用于多种病症,广泛运用于医院的神经康复科室。文章来源:财中社伟思医疗获2项医疗器械注册证 涉及多功能生物刺激反馈仪","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118160925a2424f01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118160925a2424f01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688580","159883"],"gpt_icon":0},{"id":"2484112726","title":"伟思医疗(688580.SH)取得2项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2484112726","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484112726?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:36","pubTimestamp":1731915402,"startTime":"0","endTime":"0","summary":"智通财经APP讯,伟思医疗(688580.SH)发布公告,公司于近日收到了由江苏省药品监督管理局颁发的2项《医疗器械注册证》,产品名称:多功能生物刺激反馈仪、生物刺激反馈仪。上述拿证的多功能生物刺激反馈仪产品主要是用于神经和肌肉受损功能的恢复,是市场主流的康复物理治疗产品,广泛运用于医院神经康复相关科室。新款生物刺激反馈仪是公司原有盆底电刺激产品的全面升级迭代,主要是用于各类盆底功能障碍疾病的治疗,广泛运用于医院妇产、盆底中心相关科室。上述《医疗器械注册证》的取得,将有利于进一步扩展和优化公司物理因子治疗产品线,提升公司电刺激类产品在盆底康复与康复理疗市场的综合竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09997","BK1222","688580","BK1574","BK1583","BK0251","159883","BK1100","09996"],"gpt_icon":0},{"id":"2483636312","title":"伟思医疗(688580)11月14日主力资金净卖出952.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483636312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483636312?lang=zh_cn&edition=full","pubTime":"2024-11-15 08:25","pubTimestamp":1731630322,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月14日收盘,伟思医疗报收于30.9元,下跌5.45%,换手率1.51%,成交量1.44万手,成交额4606.43万元。伟思医疗主营业务:主要从事医疗器械的研发、生产和销售,以研发创新为发展驱动力,持续投入在电刺激、磁刺激、电生理、康复机器人以及医美能量源等方向的先进技术研发,并完善产品布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111500006707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688580"],"gpt_icon":0},{"id":"2483609846","title":"伟思医疗11月14日遭主力抛售831万元 环比增加160.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483609846","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483609846?lang=zh_cn&edition=full","pubTime":"2024-11-14 15:20","pubTimestamp":1731568810,"startTime":"0","endTime":"0","summary":"11月14日, 伟思医疗股价跌5.45%,报收30.90元,成交金额4606万元,换手率1.51%,振幅7.31%,量比0.81。伟思医疗今日主力资金净流出831万元,上一交易日主力净流出319万元,今日环比增加160.50%。该股近5个交易日下跌2.34%,主力资金累计净流入686万元;近20日主力资金累计净流入663万元,其中净流入天数为9日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114153723a2368ff9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114153723a2368ff9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688580","BK0251"],"gpt_icon":0},{"id":"2483181009","title":"伟思医疗大跌5.14% 7家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2483181009","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483181009?lang=zh_cn&edition=full","pubTime":"2024-11-14 14:51","pubTimestamp":1731567088,"startTime":"0","endTime":"0","summary":"11月14日,伟思医疗股价大幅下跌,截至14点51分,伟思医疗下跌5.14%,报31.00元/股,成交4302万元,换手率1.40%,振幅6.95%。此外,数据统计显示,近半年内7家券商给予增持建议,9家券商给予买入建议。资金动向截止发稿,伟思医疗获得主力净流出695万元,其中超大单流出442万元,大单流出252万元。最新财报显示,今年三季报,伟思医疗实现营业收入2.92亿元,同比减少12.06%,净利润为7,816.63万元,同比减少23.13%,基本每股收益为0.82元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114145138a2366417&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114145138a2366417&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688580"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-07-21","address":"江苏省南京市雨花台区宁双路19号9栋","stockEarnings":[{"period":"1week","weight":-0.1185},{"period":"1month","weight":0.0358},{"period":"3month","weight":0.3595},{"period":"6month","weight":0.0734},{"period":"1year","weight":-0.3079},{"period":"ytd","weight":-0.3234}],"companyName":"南京伟思医疗科技股份有限公司","boardCode":"AI0035","perCapita":"18135股","boardName":"专用设备制造业","registeredCapital":"9577万元","compareEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.1705},{"period":"6month","weight":0.1274},{"period":"1year","weight":0.1497},{"period":"ytd","weight":0.1265}],"survey":" 南京伟思医疗科技股份有限公司主营业务为医疗器械的研发、生产和销售,公司产品主要是MyOnyx生物刺激反馈仪、瑞翼生物刺激反馈仪、经颅磁刺激仪、盆底磁刺激仪、脉冲磁场治疗仪、脉冲磁恢复仪、脉冲磁塑形仪、多参数生物反馈仪、团体生物反馈仪、表面肌电分析系统、新生儿脑电测量仪、X-walk、X-locom、科瑞达钬激光治疗机、阴道电极、直肠电极、盆底训练探头、盆底肌肉康复器、认知功能障碍治疗软件、伟思云。","serverTime":1735019013076,"listedPrice":67.58,"stockholders":"5281人(较上一季度减少0.58%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"伟思医疗(688580)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供伟思医疗(688580)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"伟思医疗,688580,伟思医疗股票,伟思医疗股票老虎,伟思医疗股票老虎国际,伟思医疗行情,伟思医疗股票行情,伟思医疗股价,伟思医疗股市,伟思医疗股票价格,伟思医疗股票交易,伟思医疗股票购买,伟思医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"伟思医疗(688580)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供伟思医疗(688580)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}